A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. by Stanhope, Kimber L et al.
UC Davis
UC Davis Previously Published Works
Title
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on 
lipid/lipoprotein risk factors for cardiovascular disease in young adults.
Permalink
https://escholarship.org/uc/item/6zz9v6bc
Journal
The American journal of clinical nutrition, 101(6)
ISSN
0002-9165
Authors
Stanhope, Kimber L
Medici, Valentina
Bremer, Andrew A
et al.
Publication Date
2015-06-01
DOI
10.3945/ajcn.114.100461
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
A dose-response study of consuming high-fructose corn
syrup–sweetened beverages on lipid/lipoprotein risk
factors for cardiovascular disease in young adults1–6
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ABSTRACT
Background: National Health and Nutrition Examination Survey
data show an increased risk of cardiovascular disease (CVD) mor-
tality with an increased intake of added sugar.
Objective: We determined the dose-response effects of consuming
beverages sweetened with high-fructose corn syrup (HFCS) at zero,
low, medium, and high proportions of energy requirements (Ereq)
on circulating lipid/lipoprotein risk factors for CVD and uric acid in
adults [age: 18–40 y; body mass index (in kg/m2): 18–35].
Design: We conducted a parallel-arm, nonrandomized, double-
blinded intervention study in which adults participated in 3.5 inpa-
tient days of baseline testing at the University of California Davis
Clinical and Translational Science Center’s Clinical Research Center.
Participants then consumed beverages sweetened with HFCS at 0%
(aspartame sweetened, n = 23), 10% (n = 18), 17.5% (n = 16), or 25%
(n = 28) of Ereq during 13 outpatient days and during 3.5 inpatient
days of intervention testing at the research center. We conducted 24-h
serial blood collections during the baseline and intervention testing
periods.
Results: Consuming beverages containing 10%, 17.5%, or 25%
Ereq from HFCS produced significant linear dose-response in-
creases of lipid/lipoprotein risk factors for CVD and uric acid: post-
prandial triglyceride (0%: 0 6 4; 10%: 22 6 8; 17.5%: 25 6 5:
25%: 37 6 5 mg/dL, mean of D 6 SE, P , 0.0001 effect of HFCS-
dose), fasting LDL cholesterol (0%: 21.0 6 3.1; 10%: 7.4 6 3.2;
17.5%: 8.2 6 3.1; 25%: 15.9 6 3.1 mg/dL, P , 0.0001), and 24-h
mean uric acid concentrations (0%: 20.13 6 0.07; 10%: 0.15 6
0.06; 17.5%: 0.30 6 0.07; 25%: 0.59 6 0.09 mg/dL, P , 0.0001).
Compared with beverages containing 0% HFCS, all 3 doses of
HFCS-containing beverages increased concentrations of postpran-
dial triglyceride, and the 2 higher doses increased fasting and/or
postprandial concentrations of non–HDL cholesterol, LDL choles-
terol, apolipoprotein B, apolipoprotein CIII, and uric acid.
Conclusions: Consuming beverages containing 10%, 17.5%, or 25%
Ereq from HFCS produced dose-dependent increases in circulating
lipid/lipoprotein risk factors for CVD and uric acid within 2 wk.
These results provide mechanistic support for the epidemiologic ev-
idence that the risk of cardiovascular mortality is positively associ-
ated with consumption of increasing amounts of added sugars. This
trial was registered at clinicaltrials.gov as NCT01103921. Am J
Clin Nutr 2015;101:1144–54.
Keywords: apolipoprotein CIII, fructose, risk factors, sugar, uric
acid
INTRODUCTION
Considerable epidemiologic evidence suggests that increased
intake of added sugars, sucrose and/or high-fructose corn syrup
(HFCS),7 or sugar-sweetened beverages is associated with dys-
lipidemia, cardiovascular disease (CVD), and metabolic syn-
drome (1). Recent evidence from National Health and Nutrition
Examination Survey III suggests that the higher the intake of
added sugar, the greater the risk (2). The adjusted HRs of CVD
mortality across quintiles of percentage of daily calories con-
sumed from added sugar (quintile 1: 0–9.59%; quintile 2: 9.6–
13.09%; quintile 3: 13.1–16.69%; quintile 4: 16.7–21.29%;
quintile 5: $21.3% of daily calories) were 1.00 (reference) for
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quintile 1, 1.07 (95% CI: 1.02–1.12) for quintile 2, 1.18 (95%
CI: 1.06–1.31) for quintile 3, 1.38 (95% CI: 1.11–1.70) for
quintile 4, and 2.03 (95% CI: 1.26–3.27) for quintile 5 (P =
0.004; n = 11,733) (2). These data suggest that the average
amount of added sugar consumption in the United States,w13–
14% of daily calories for adults 20–60 y of age (3) and 16% for
children and adolescents (4), is associated with an 18% increase
in CVD mortality risk (2). However, investigators of a recent
dose-response study, in which ad libitum diets of men and
women were supplemented with beverages containing 8%, 18%,
or 30% energy requirement (Ereq) from sucrose or HFCS for
10 wk (5, 6), have reported that consumption of added sugar
does not increase fasting cholesterol and LDL cholesterol (5)
and that there were no differences between the 3 doses of sugar
in 24-h circulating triglyceride and uric acid concentrations (6).
We have conducted a dose-response study in which the ad li-
bitum diets of young men and women were supplemented with
HFCS-sweetened beverages for 2 wk. Our objective was to
determine the dose-response effects of consuming of beverages
providing 0%, 10%, 17.5%, or 25% Ereq from HFCS (Ereq-
HFCS) on circulating concentrations of lipid/lipoprotein risk
factors for CVD and uric acid.
METHODS
Participants in this study are a subgroup from an NIH-funded
investigation in which a total of 187 participants assigned to 8
experimental groups were studied. A primary objective of this 5-y
investigation was to compare the metabolic effects of consuming
beverages containing fructose, glucose, or HFCS at 25% Ereq,
and the results from the first 48 subjects to complete the study
protocol in these experimental groups (n = 16/group) have been
reported (7). The current article reports the results from 85
participants consuming beverages containing 0% (n = 23), 10%
(n = 18), 17.5% (n = 16), and 25% (n = 28) Ereq from HFCS.
Participants, who were recruited through an Internet listing
(craigslist.com) and local postings of flyers, underwent telephone
and in-person interviews with medical history, complete blood
count, and serum biochemistry panel to assess eligibility. In-
clusion criteria included age 18–40 y and BMI 18–35 kg/m2 with
a self-report of stable body weight during the prior 6 months.
Exclusion criteria included diabetes (fasting glucose.125 mg/dL),
evidence of renal or hepatic disease, fasting plasma triglyceride
.400 mg/dL, hypertension (.140/90 mm Hg), hemoglobin
,8.5 g/dL, and surgery for weight loss. Individuals who
smoked, habitually ingested .2 alcoholic beverages/d, exer-
cised .3.5 h/wk at a level more vigorous than walking, or used
thyroid, lipid-lowering, glucose-lowering, antihypertensive, an-
tidepressant, or weight loss medications were also excluded.
Assignment to the experimental groups was not randomized;
by design, the experimental groups were matched for sex, BMI,
and concentrations of fasting triglyceride, cholesterol, HDL
cholesterol, and insulin in plasma collected during the in-person
interviews.
For the 5 wk before study, subjects who were scheduled for
participation were asked to limit daily consumption of sugar-
containing beverages to no more than one 8-oz serving of fruit
juice and to discontinue consumption of any vitamin, mineral,
dietary, or herbal supplements. Ninety-seven subjects were en-
rolled in the experimental groups consuming 0%, 10%, 17.5%, or
25% Ereq-HFCS. Five subjects withdrew or were dismissed from
the study before the start of the intervention for reasons that
included scheduling problems, new job, dissatisfaction with
inpatient meals, family emergency, and personal anxiety. Of the
7 subjects who participated in intervention, one (0% group)
withdrew due to job-related conflict, one (10% group) was lost to
follow-up due to loss of contact, one (17.5% group) withdrew due
to a family emergency, and 4 (25% group) did not complete the
study for other reasons [one withdrew due to back pain (one
fasting intervention sample was collected from this subject), one
withdrew due to personal anxiety, one was dismissed for medical
issues not apparent during screening, and one was dismissed for
illness (e.g., flu-like symptoms)]. A sensitivity analysis was
conducted, which demonstrated that the higher number of
noncompleters in the 25% group did not influence the results (see
Supplemental Figure 1). A total of 85 subjects completed the
dose-response study. The data from one subject (17.5% group)
were included in the fasting analyses but not postprandial
analyses because a family emergency prevented completion of
the 24-h serial blood collection during the intervention period.
The sample size calculation, based on the fasting apolipoprotein
B (apoB) results generated during a previous study (8), indicated
that 25 subjects per group would be sufficient to detect differ-
ences between the 25% Ereq and 0% Ereq groups. This number
was not achieved in all groups due to insufficient funding. The
larger number of subjects in the 25% group is due to additional
funding (R01 HL107256) being obtained to conduct mechanistic
studies in participants from this group. The 28 participants who
consumed 25% Ereq-HFCS included 16 participants whose
results were previously reported (7). A comparison of these 16
subjects with the 12 additional subjects in the 25% group is
provided in Supplemental Table 1 and reveals no differences
in baseline parameters and outcome responses.
This was a parallel-arm, double-blinded diet intervention study
with 3 phases: 1) a 3.5-d inpatient baseline period during which
subjects resided at the University of California Davis Clinical
and Translational Science Center’s Clinical Research Center
(CCRC), consumed a standardized baseline diet, and partici-
pated in experimental procedures; 2) a 12-d outpatient in-
tervention period during which subjects consumed their assigned
sweetened beverages providing 0% (aspartame sweetened) or
10%, 17.5%, or 25% Ereq-HFCS along with their usual ad li-
bitum diets; and 3) a 3.5-d inpatient intervention period during
which subjects resided at the CCRC and consumed standardized
diets that included the sweetened beverages, and all experi-
mental procedures were repeated.
Inpatient diets
During days 2 and 3 of the baseline and intervention inpatient
periods, subjects consumed energy-balanced meals consisting of
conventional foods. Daily energy requirements were calculated
by the Mifflin equation (9), with adjustment of 1.3 for activity on
the days of the 24-h serial blood collections and adjustment of 1.5
for the other days. The baseline diet contained 55% Ereq mainly
as low-fiber complex carbohydrate (i.e., white bread, white rice,
regular pasta), 30% from fat, and 15% from protein. The meals
during the inpatient intervention period included the assigned
study beverages and were as identical as possible to baseline
meals, except for the substitution of the sugar-sweetened
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beverage in place of isocaloric amounts of complex carbohydrate.
The intervention meals contained 19–20 g fiber/2000 kcal fiber,
and the baseline meals contained 22 g fiber/2000 kcal. The
timing of inpatient meals and the energy distribution were as
follows: breakfast, 0900 (25%); lunch, 1300 (35%); and dinner,
1800 (40%).
Study beverages and outpatient diet
HFCS-containing beverages were sweetened with HFCS-55
(Isosweet 5500, 55% fructose, 45% glucose; Skidmore Sales and
Distributing), flavored with an unsweetened drink mix (Kool-
Aid; Kraft Inc.). A fruit-flavored aspartame drink mix (Market
Pantry) was used to prepare the 0% Ereq-HFCS beverages and to
augment the sweetness of the 10% Ereq-HFCS beverages. Par-
ticipants were blinded to their beverage assignment, as were all
CCRC and study personnel who interacted with participants
or analyzed samples. Voluntary feedback from participants in-
dicated that they were unable to distinguish between beverages
containing aspartame or HFCS. The amount (grams) of beverage
provided was standardized among the 4 groups and based on
energy requirements [calculated with the Mifflin equation (9)
plus 1.5 activity adjustment]. During the 12-d outpatient phase of
the study, participants were instructed to drink one serving of
study beveragewith eachmeal, to consume their usual diet, and to
not consume other sugar-sweetened beverages, including fruit
juice. To monitor compliance of beverage consumption (10, 11),
the study beverages contained a biomarker (riboflavin) that was
measured fluorimetrically in urine samples collected at the times
of beverage pickup. Subjects were informed about the biomarker
but were not provided information regarding its identity. Fasting
urinary riboflavin concentrations (Supplemental Figure 2)
following 9 d and 13 d of unmonitored beverage consumption
were not different from those following one day of monitored
beverage consumption at the CCRC, suggesting good and
comparable compliance in all groups.
Procedures
The 24-h serial blood collections (7) were conducted on the
third day of the baseline (0 wk) and intervention (2 wk) inpatient
periods. Three fasting blood samples were collected at 0800,
0830, and 0900 h. Twenty-nine postprandial blood samples were
collected at 30- to 60-min intervals until 0800 the following
morning. Additional 6-mL blood samples were collected at the
fasting time points (0800, 0830, and 0900 h) and also at the late-
evening time points (2200, 2300, and 2400 h). The additional
plasma from the 3 fasting samples was pooled, as was that from
the 3 late-evening postprandial samples; multiple aliquots of each
pooled sample were stored at2808C. The plasma concentrations
of triglyceride and uric acid were measured at all time points
and calculated for mean 24-h concentration and for 24-h
AUC by the trapezoidal method. The concentrations of non–
HDL cholesterol, LDL cholesterol, apoB, apolipoprotein CIII
(apoCIII), and apolipoprotein AI were measured during the
fasting and late-evening postprandial period. These postprandial
measures were conducted on samples collected or pooled from
the 2200, 2300, and 2400 h time points because this was the
period during which peak postprandial triglyceride concentra-
tions were observed in our previous study (8). Lipid, lipoprotein,
and uric acid concentrations were measured with a Polychem
Chemistry Analyzer (PolyMedCo Inc.) with reagents from
MedTest DX. The intra- and interassay CVs during the time
period when these measurements were conducted (2010–2014)
were as follows: triglyceride: 3.1%, 7.6% (intra-assay, inter-
assay); total cholesterol: 2.3%, 4.4%; HDL cholesterol: 3.0%,
5.5%; direct LDL cholesterol: 2.4%, 4.7%; apoB: 3.5%, 6.9%;
apoCIII: 2.0%, 6.5%; and uric acid: 1.9, 5.6%.
Ethics
The study was conducted in accordance with an experimental
protocol that was approved by the UC Davis Institutional Review
Board, and participants provided written informed consent.
Statistical analyses
The absolute change (D) at 2 wk of intervention compared
with the 0-wk baseline value for each outcome was tested for
a dose-response trend in a general linear model (SAS 9.3; SAS
Institute), adjusted for sex, BMI, and outcome concentration
[outcome] at baseline by using HFCS dose (0%, 10%, 17.5%,
25%) as a continuous variable. Departures from linearity were
tested with polynomial terms by using the same model. The
proportion of variance explained by each covariate was calcu-
lated as follows: (type III sum of squares/corrected total sum of
squares) 3 100 (Supplemental Table 2). A secondary trend-
testing general linear model that also included Dbody weight as
a continuous covariate was conducted. The D for each outcome
was also analyzed in a general linear model (SAS 9.3), adjusted
for sex, BMI, and [outcome] at baseline, with HFCS-group (1, 2,
3, 4) as a categorical variable. This model allowed for testing of
outcomes that were significantly changed from baseline con-
centrations as least squares means of D different from zero and
identified significant differences between groups by Tukey’s
multiple-comparisons test. The Dnon–HDL cholesterol, LDL
cholesterol, and apoB concentrations were further investigated
in the adjusted general linear model that included HFCS
dose (0%, 10%, 17.5%, 25%) as a continuous variable and
Dpostprandial triglyceride, apoCIII, and uric acid as continuous
covariates, singly and in combination. This model was also used
to test for relations between Dpostprandial triglyceride, apoCIII,
and uric acid. Sixteen outcomes were tested for nominal sig-
nificance (P , 0.05) and notated when the effect of HFCS-dose
did not obtain a level of significance corrected for 16 compar-
isons (P , 0.0031). Data presented in Table 1 are means 6
SDs; all other data are means 6 SEs.
RESULTS
There were no significant differences between the 4 experi-
mental groups in anthropomorphic or metabolic parameters at
baseline (Table 1).
Effect of HFCS-dose
The outcome means at 0 wk and at the end of the 2-wk in-
tervention by group, as well as the P values for the effects of
HFCS-dose, are presented in Table 2. The consumption of
beverages containing 0%, 10%, 17.5%, and 25% Ereq-HFCS
produced positive dose-response effects that did not deviate
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significantly from linear in all outcomes presented. All out-
comes, except Dbody weight, fasting triglyceride, and fasting
apoCIII, retained significance after correction for multiple
comparisons (P , 0.0031). Supplemental Table 2 shows the
variance explained by HFCS-dose, sex, BMI, [outcome] at
baseline, and the complete model for each outcome. The D24-h
mean uric acid concentration was the outcome most affected by
HFCS-dose (proportion of variance: 36%; P , 0.0001) and
Dfasting triglyceride was the least affected (proportion of vari-
ance: 6%; P = 0.019). When tested in the general linear model
that included adjustment for the Dbody weight, the effect of
HFCS-dose remained significant for all outcomes with the ex-
ception of fasting triglyceride (Supplemental Table 3).
Effect of HFCS-group
The least squares means of each Doutcome (2 wk minus 0 wk
with adjustment for sex, BMI, and [outcome] at baseline) are
presented in Figure 1A–D and labeled for significant effect of
HFCS-group and differences between groups and from baseline
[significance notations in red indicate that difference did not
retain significance after correction for multiple comparisons
(P , 0.0031)]. With the exception of Dbody weight and fasting
triglyceride, all outcomes presented in Figure 1A–D were sig-
nificantly affected by HFCS-group. Compared with 0% Ereq-
HFCS, consumption of beverages containing 25% Ereq-HFCS
resulted in significantly higher concentrations of postprandial
non–HDL cholesterol, LDL cholesterol, and triglyceride, as well
as fasting and 24-h mean uric acid (all P , 0.0001, Tukey’s
multiple-comparisons test); fasting non-HDL-C and LDL and
postprandial apoB and apoCIII (all P , 0.001); fasting apoB
(P , 0.01); and 24-h mean triglyceride (P, 0.05). The changes
measured during consumption of 17% Ereq-HFCS were
significantly higher compared with those induced by 0%
Ereq-HFCS for postprandial apoCIII (P , 0.001); postprandial
non–HDL cholesterol and triglycerides, as well as 24-h mean
uric acid (all P , 0.01); and fasting non–HDL cholesterol and
uric acid, as well as postprandial LDL cholesterol and apoB (all
P , 0.05). Consumption of the 10% Ereq-HFCS beverages,
which is comparable to consuming slightly more than half of
a 12-oz (355 mL) can of soda (40 g sugar/can) with each of the
3 major meals, increased concentrations of postprandial tri-
glyceride compared with 0% Ereq-HFCS beverages (P , 0.05).
The increases of non–HDL cholesterol, LDL cholesterol, apoB,
and 24-h mean uric acid were larger in men than in women (P =
0.0025 – P = 0.038, effect of sex; Supplemental Figure 3A–C).
As shown in Figure 2A–D, consumption of HFCS resulted in
increases of uric acid concentrations that were consistent
throughout the 24-h collection period within each dose group.
The 24-h uric acid AUC was significantly increased in the 25%
group compared with both the 0% and 10% groups (Figure 2E).
The differential effects of HFCS compared with complex car-
bohydrate on 24-h circulating triglyceride concentrations (Fig-
ure 3) were most marked during the late-evening postprandial
period (Figure 1D). HFCS consumption consistently resulted in
a third triglyceride peak 4–6 h after dinner, whereas consump-
tion of 55% Ereq complex carbohydrate at baseline or along
with aspartame-sweetened beverages did not (Figure 3A–D).
Relations between outcomes
DPostprandial triglyceride, apoCIII, and uric acid concentra-
tions were tested in the adjusted general linear regression model
for their relation to each other (data not shown) and for their
potential contributions to Dfasting and postprandial non–HDL
cholesterol, LDL cholesterol, and apoB. The Duric acid was not
significantly related to DapoCIII or postprandial triglyceride
(data not shown). The Dpostprandial triglyceride and Dfasting
or postprandial apoCIII were highly correlated, especially
Dpostprandial apoCIII and D24-h mean triglyceride concentra-
tions (data not shown). The Dpostprandial apoCIII was a highly
significant covariate (proportion of variance = 35%, P, 0.0001)
in the adjusted model testing the effects of HFCS dose on D24-h
mean triglyceride, and D24-h mean triglyceride was an almost
TABLE 1
Description of participants at baseline by HFCS content of beverage1
HFCS 0% HFCS 10% HFCS 17.5% HFCS 25%
Men/women, n 11/12 9/9 7/9 15/13
Age, y 25 6 62 28 6 6 24 6 5 27 6 7
BMI, kg/m2 24.8 6 3.3 24.9 6 3.8 24.2 6 3.3 24.9 6 4.0
Body fat, % 27.1 6 9.8 26.8 6 7.4 26.3 6 9.6 25.9 6 9.9
Energy requirement,3 kcal/d 2354 6 322 2323 6 247 2326 6 375 2390 6 350
Waist circumference, cm 74.8 6 6.2 75.3 6 8.7 73.1 6 8.0 76.3 6 9.7
Systolic blood pressure, mm Hg 112 6 12 115 6 10 115 6 8 117 6 10
Diastolic blood pressure, mm Hg 69 6 9 73 6 8 71 6 5 74 6 9
Fasting glucose, mg/dL 91.3 6 7.1 89.2 6 8.0 87.2 6 6.5 89.9 6 6.5
Fasting insulin, mU/mL 12.8 6 5.5 11.8 6 3.4 11.7 6 3.0 13.0 6 5.2
Fasting triglyceride, mg/dL 101 6 53 122 6 70 97 6 34 108 6 50
Fasting cholesterol, mg/dL 149 6 25 162 6 27 165 6 35 158 6 34
Fasting HDL cholesterol,4 mg/dL 36 6 7/43 6 7 42 6 11/46 6 12 44 6 7/48 6 11 42 6 8/50 6 18
HFCS provided in beverage, g/d 0 6 0 63 6 7 111 6 18 162 6 24
1Values are means 6 SDs. HFCS, high-fructose corn syrup.
2All variables (excepting HFCS in beverage): P . 0.05 for differences among groups at baseline (general linear model
ANOVA with HFCS-group as categorical variable: SAS 9.3).
3Energy requirement calculated by the Mifflin equation with 1.5 adjustment for physical activity.
4Data from men/women.
DOSE-RESPONSE EFFECTS OF CONSUMING HFCS 1147
 at UNIVERSITY O
F CALIFO
RNIA DAVIS on July 6, 2015
ajcn.nutrition.org
D
ow
nloaded from
 
equally significant covariate (proportion of variance = 30%, P ,
0.0001) in the model testing the effects of HFCS dose on
Dpostprandial apoCIII.
Despite their strong correlation, Dpostprandial triglyceride,
whether indexed as the 24-h mean or the late-evening post-
prandial peak (or mean of postmeal peaks), was not a significant
covariate in the models testing the effects of HFCS dose on
Dnon–HDL cholesterol, LDL, or apoB (data not shown),
whereas DapoCIII was highly related. In Table 3, we present the
proportion of variances and P values for 4 adjusted models that
tested the effects of HFCS dose, HFCS dose and Duric acid,
HFCS dose and DapoCIII, and HFCS dose with Duric acid and
DapoCIII together on the Dfasting and postprandial non–HDL
cholesterol, LDL cholesterol, and apoB. Singly, Duric acid and
DapoCIII were significant covariates for all 6 outcomes and
reduced the proportion of variance for the effect of HFCS dose
TABLE 2
Body weight and plasma concentrations of risk factors before and 2 wk after consuming 0%, 10%, 17.5%, or 25% Ereq as
HFCS-sweetened beverages in young men and women1
Outcome
HFCS dose
Effect of dose2 (P value)0% (n = 23) 10% (n = 18) 17.5% (n = 16) 25% (n = 28)
Body weight, kg
0 wk 71.8 6 2.2 70.9 6 2.4 69.9 6 3.6 72.9 6 2.7 0.0143
2 wk 71.7 6 2.2 70.9 6 2.4 70.2 6 3.7 73.7 6 2.8
FST non–HDL cholesterol, mg/dL
0 wk 110 6 5 118 6 6 119 6 8 112 6 6 ,0.0001
2 wk 107 6 5 126 6 7 126 6 7 128 6 6
PP non–HDL cholesterol, mg/dL
0 wk 101 6 5 111 6 5 113 6 8 103 6 5 ,0.0001
2 wk 99 6 5 120 6 7 126 6 8 124 6 6
FST LDL cholesterol, mg/dL
0 wk 84 6 5 95 6 5 93 6 8 91 6 5 ,0.0001
2 wk 83 6 6 102 6 6 102 6 6 107 6 6
PP LDL cholesterol, mg/dL
0 wk 81 6 5 89 6 4 89 6 7 86 6 5 ,0.0001
2 wk 80 6 4 99 6 7 99 6 7 105 6 6
FST apoB, mg/dL
0 wk 64.8 6 3.6 69.0 6 3.3 69.4 6 5.6 69.6 6 3.5 0.0002
2 wk 65.1 6 3.0 73.6 6 3.9 73.2 6 4.4 80.0 6 4.1
PP apoB, mg/dL
0 wk 62.0 6 3.6 65.3 6 3.1 66.0 6 4.9 65.3 6 3.4 ,0.0001
2 wk 61.3 6 3.0 70.1 6 4.0 73.7 6 4.7 77.4 6 4.2
FST apoCIII, mg/dL
0 wk 7.31 6 0.52 8.63 6 0.65 8.08 6 0.48 8.20 6 0.50 0.00543
2 wk 7.25 6 0.47 8.34 6 0.55 8.55 6 0.52 8.84 6 0.52
PP apoCIII, mg/dL
0 wk 6.71 6 0.62 7.82 6 0.58 7.48 6 0.52 7.40 6 0.46 ,0.0001
2 wk 6.55 6 0.51 8.13 6 0.53 8.65 6 0.55 8.48 6 0.55
FST uric acid, mg/dL
0 wk 4.57 6 0.22 4.27 6 0.29 4.40 6 0.20 4.55 6 0.22 ,0.0001
2 wk 4.51 6 0.20 4.42 6 0.30 4.70 6 0.23 5.03 6 0.24
24-h Mean uric acid, mg/dL
0 wk 4.35 6 0.21 4.10 6 0.29 4.22 6 0.21 4.27 6 0.21 ,0.0001
2 wk 4.22 6 0.19 4.25 6 0.31 4.56 6 0.23 4.86 6 0.24
FST triglyceride, mg/dL
0 wk 101 6 11 122 6 17 97 6 9 108 6 9 0.0193
2 wk 98 6 10 114 6 14 97 6 9 119 6 10
24-h Mean triglyceride, mg/dL
0 wk 109 6 14 134 6 19 109 6 10 119 6 10 0.0014
2 wk 104 6 12 135 6 20 119 6 12 131 6 12
PP triglyceride, mg/dL
0 wk 94 6 14 125 6 23 100 6 11 108 6 11 ,0.0001
2 wk 94 6 13 147 6 25 125 6 14 145 6 14
1Values are means 6 SEs. apoB, apolipoprotein B; apoCIII, apolipoprotein CIII; Ereq, energy requirement; FST, fasting;
HFCS, high-fructose corn syrup; PP, postprandial; D, absolute change.
2The absolute change (D from 2-wk intervention with sweetened beverage compared with 0 wk baseline) for each outcome
was analyzed in a general linear model (SAS 9.3) with dose of HFCS in beverage as a continuous variable (0%, 10%, 17.5%, 25%)
and adjustment for sex, BMI, and [outcome] at baseline; departures from linearity were tested with polynomial terms in the same
model. All outcomes exhibited trends that did not significantly deviate from linear.
3Nominally significant outcome that is not significant (P , 0.0031) when corrected for 16 comparisons.
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by 33–77%. In combination, both Duric acid and DapoCIII re-
mained significant covariates and reduced the proportion of
variance estimates for the effect of HFCS dose by 76–95%.
DISCUSSION
This study demonstrates for the first time that established risk
factors for CVD, plasma concentrations of non–HDL cholesterol,
LDL cholesterol, and apoB (12), increase in a dose-dependent
manner in young adults consuming beverages providing 10%,
17.5%, or 25% Ereq from HFCS for 2 wk. The dose-dependent
increases of these risk factors for CVD, which were shown to be
statistically independent of body weight gain, provide mechanistic
support for the recent epidemiologic findings that there is increased
risk of CVD mortality with increased intake of added sugar across
quintiles (2). The significant and independent correlations of both
DapoCIII and uric acid with Dnon–HDL cholesterol, LDL choles-
terol, and apoB (see Supplemental Discussion for more details)
suggest the potential for 2 separate pathways by which consumption
of HFCS increases these risk factors for CVD.
The increases of late-night postprandial triglyceride concentra-
tions during consumption of all 3 doses of HFCS compared with 0%
Ereq-HFCS support our previous work (7, 8) but do not support
a meta-analysis concluding that fructose in isocaloric exchange for
other carbohydrate does not increase postprandial triglyceride (13)
(see Supplemental Discussion for details and also Supplemental
Figure 4A,C). Consumption of fructose-containing sugars increases
circulating triglyceride because fructokinase, which catalyzes the
initial phosphorylation of dietary fructose, is not regulated by he-
patic energy status (14). This results in unregulated hepatic fructose
uptake (15–17), with most of the ingested fructose being metabo-
lized in the liver and little reaching the systemic circulation (18).
The excess substrate leads to increased de novo lipogenesis (8),
which may increase the intrahepatic lipid supply directly (19, 20),
via synthesis of fatty acids, and indirectly, by inhibiting fatty acid
oxidation (21, 22). Increased intrahepatic lipid content promotes
VLDL production and secretion (23, 24), leading to increased
concentrations of postprandial triglyceride (25). Postprandial hy-
pertriglyceridemia has been recently reviewed as an important risk
factor for CVD (26) (see Supplemental Discussion).
FIGURE 1 Effects of consuming beverages containing 0%, 10%, 17.5%, and 25% Ereq-HFCS. The least squares means (adjusted for sex, BMI, and
[outcome] at baseline)6 SEs of (A) Dbody weight; (B) DFST and PP plasma non–HDL cholesterol, LDL cholesterol, and apoB concentrations; (C) DFST and
PP plasma apoCIII concentrations and DFST and 24-h mean plasma uric acid concentrations; and (D) DFST, 24-h mean, and PP plasma triglyceride
concentrations in young men and women after consuming beverages providing 0% (n = 23), 10% (n = 18), 17.5% (n = 16), or 25% (n = 28) of Ereq from
HFCS for 2 wk. *P , 0.05, **P , 0.01, ***P , 0.001, ****P , 0.0001, effect of HFCS group; 2-factor (HFCS group, sex) ANCOVA of D with adjustment
for BMI and [outcome] at baseline. aD different from bD or bcD and abD different from cD, Tukey’s multiple-comparisons test. +P , 0.05, ++P , 0.01, +++P ,
0.001, ++++P , 0.0001, least squares mean different from zero. Significance notations in red indicate that difference did not retain significance after correction
for multiple comparisons (P , 0.0031). apoB, apolipoprotein B; apoCIII, apolipoprotein CIII; Ereq, energy requirement; FST, fasting; HFCS, high-fructose
corn syrup; PP, postprandial; D, absolute change.
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This is the first report to our knowledge that consumption of
HFCS, or any sugar, increases plasma concentrations of apoCIII
in humans. We have, however, reported that plasma apoCIII
increased in rhesus monkeys provided with fructose-sweetened
beverages for 6 mo (27). The current increases of apoCIII may
simply reflect the effect of HFCS to increase VLDL production,
because most VLDL particles are secreted as apoCIII-containing
VLDL (28). However, glucose induces apoCIII transcription
in rat and human hepatocytes via a mechanism involving the
transcription factor, carbohydrate response element-binding
protein (29). This mechanism could be relevant to consumption
of HFCS because a significant proportion of a large fructose dose
is converted into glucose (30) and because HFCS contains
glucose. In addition, fructose-fed rats treated with carbohydrate
response element-binding protein antisense exhibited a decreased
rate of hepatic triglyceride secretion (31), suggesting a role for
carbohydrate response element-binding protein in the lipogenic
effects of fructose feeding. Plasma apoCIII strongly predicts
FIGURE 2 The 24-h circulating uric acid concentrations during consumption of complex carbohydrate and during consumption of sweetened beverages
containing 0%, 10%, 17.5%, and 25% of Ereq-HFCS. Circulating 24-h uric acid plasma concentrations during consumption of energy-balanced baseline diets
containing 55% Ereq complex carbohydrate at 0 wk and during consumption of energy-balanced intervention diets containing isocaloric amounts of
carbohydrate as complex carbohydrate and (A) 0% Ereq-HFCS (n = 23), (B) 10% Ereq-HFCS (n = 18), (C) 17.5% Ereq-HFCS (n = 15), or (D) 25%
Ereq-HFCS (n = 28) at 2 wk. (E) The change in circulating 24-h uric acid plasma concentrations (2 wk – 0 wk) quantified for each group as D24-h uric acid
AUC. ****P , 0.0001, effect of HFCS group; 2-factor (HFCS group, sex) ANCOVA of D with adjustment for BMI and [outcome] at baseline. aD different
from bD, Tukey’s multiple-comparisons test. +P , 0.05, ++++P , 0.0001, least squares mean different from zero. Significance notations in red indicate that
difference did not retain significance after correction for multiple comparisons (P , 0.0031). Data are means 6 SEs. CHO, carbohydrate; Ereq, energy
requirement; HFCS, high-fructose corn syrup; D, absolute change.
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CVD (32) and loss-of-function mutations in the apoCIII gene are
associated with lower triglyceride concentrations and reduced
risk of ischemic CVD (33).
The unregulated phosphorylation of fructose to fructose-1-
phosphate by fructokinase, which results in conversion of ATP to
AMP and a depletion of inorganic phosphate, leads to uric acid
production via the purine degradation pathway (17). It has also
been reported that a high-fructose diet increases de novo purine
biosynthesis in humans, and this also contributes to increased uric
acid production (34). Our results regarding the proportion of
variation explained by HFCS-dose suggest that these pathways
are highly sensitive to the dose of fructose. These results do not
support the conclusion from a meta-analysis that isocaloric ex-
change of fructose for other carbohydrate does not affect serum
uric acid concentrations in nondiabetic subjects (35) (see Sup-
plemental Discussion for details and Supplemental Figure 5A,
C). Uric acid is also a potential mediator of metabolic disease,
with most recent studies, but not all (36), showing that it is
FIGURE 3 The 24-h circulating triglyceride concentrations during consumption of complex carbohydrate and during consumption of sweetened
beverages containing 0%, 10%, 17.5%, and 25% of Ereq-HFCS. Circulating 24-h triglyceride plasma concentrations during consumption of energy-balanced
baseline diets containing 55% Ereq complex carbohydrate at 0 wk and during consumption of energy-balanced intervention diets containing isocaloric
amounts of carbohydrate as complex carbohydrate and (A) 0% Ereq-HFCS (n = 23), (B) 10% Ereq-HFCS (n = 18), (C) 17.5% Ereq-HFCS (n = 15), or (D)
25% Ereq-HFCS (n = 28) at 2 wk. (E) The change in circulating 24-h triglyceride plasma concentrations (2 wk – 0 wk) quantified for each group as D24-h uric
acid AUC. *P, 0.05, effect of HFCS group; 2-factor (HFCS group, sex) ANCOVA of D with adjustment for BMI and [outcome] at baseline. aD different from
bD, Tukey’s multiple-comparisons test. ++P , 0.01, least squares mean different from zero. Significance notations in red indicate that difference did not retain
significance after correction for multiple comparisons (P , 0.0031). Data are means 6 SEs. CHO, carbohydrate; Ereq, energy requirement; HFCS, high-
fructose corn syrup; D, absolute change.
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strongly associated and predictive of metabolic syndrome, fatty
liver, and CVD (37–39). In one study, an HR of 1.14 for coro-
nary heart disease events was documented for every 0.5-mg/dL
increase of uric acid concentrations (40). The similar increases
induced by the 25% Ereq-HFCS dose in just 2 wk [+0.5 6 0.1
(fasting), +0.6 6 0.1 mg/dL (24-h mean)] suggest that con-
sumption of HFCS can have clinically relevant effects to in-
crease circulating uric acid.
Our results do not support the recent reports that adults
consuming beverages containing 8%, 18%, or 30% Ereq as su-
crose or HFCS for 10 wk exhibited no differences of total
cholesterol or LDL cholesterol (5) and 24-h uric acid and tri-
glyceride AUC responses (6) between doses. The results from
these studies (6) and the present study are starkly contrasting. For
example, although Yu et al. (6) reported no differences in the 24-h
uric acid AUC “response to the 6 different interventions at
baseline or post-testing,” we report that consumption of the 25%
Ereq-HFCS dose increased 24-h uric acid AUC over baseline
(Figure 2E: 14.06 2.2 mg/dL3 24 h, P, 0.0001, least squares
mean significantly different from zero, ANCOVA) and com-
pared with 10% Ereq-HFCS (+12.8 mg/dL 3 24 h, P , 0.0001,
Tukey’s multiple-comparisons test). Possible explanations for
the contrasting results include the use of milk as a vehicle for the
sugars, lack of a control group, the statistical analyses em-
ployed, and lack of an objective measure of compliance (see
Supplemental Discussion) (6).
A strength of the current study was the presence of a biomarker in
the study beverages, which provided an objective measure of
compliance. Furthermore, the participants’ knowledge of the bio-
marker likely contributed to the excellent degree of compliance, as
evidenced by the highly significant dose-response effects obtained
for most of the outcomes. The 3.5-d inpatient periods during
baseline and at the end of intervention, which ensured that the study
results were not confounded by noncompliance or variations in diet
or physical activity during the days immediately preceding the
blood collection procedures, are an additional strength.
A limitation of the study was that it was not randomized, thus
potentially introducing bias in the assignment of subjects to the
TABLE 3
Relation of Duric acid and apoCIII with the HFCS-induced increases in non–HDL cholesterol, LDL cholesterol, and
apoB1
Risk factor/index Model 12: dose
Model 23 Model 34 Model 45
Dose Duric acid6 Dose DapoCIII Dose Duric acid6 DapoCIII
DFST non–HDL cholesterol
% Variance7: covariate 15 4 8 8 138 2 6 118
P value ,0.0001 0.033 0.0017 0.0016 ,0.0001 0.11 0.0025 ,0.0001
% Variance: model 29 38 43 49
DPP non–HDL cholesterol
% Variance: covariate 24 9 7 8 129 2 6 119
P value ,0.0001 0.0007 0.0036 0.0010 ,0.0001 0.063 0.0022 ,0.0001
% Variance: model 37 43 49 55
DFST LDL cholesterol
% Variance: covariate 18 4 11 12 78 2 9 58
P value ,0.0001 0.023 0.0003 0.0003 0.0051 0.066 0.0005 0.0080
% Variance: model 28 39 35 44
DPP LDL cholesterol
% Variance: covariate 20 7 6 12 88 4 5 68
P value ,0.0001 0.0051 0.0066 0.0002 0.0026 0.018 0.0043 0.011
% Variance: model 35 38 39 44
DFST apoB
% Variance: covariate 14 3 8 7 108 1 7 88
P value 0.0002 0.050 0.0017 0.0030 0.0006 0.16 0.0026 0.0009
% Variance: model 28 37 38 45
DPP apoB
% Variance: covariate 20 5 10 7 89 1 9 79
P value ,0.0001 0.0097 0.0006 0.0033 0.0026 0.19 0.0005 0.0019
% Variance: model 30 37 38 47
1apoB, apolipoprotein B; apoCIII, apolipoprotein CIII; FST, fasting; HFCS, high-fructose corn syrup; PP, postprandial;
D, absolute change.
2Model 1: general linear model with dose (0%, 10%, 17.5%, 25%) as a continuous covariate and adjustment for sex,
BMI, and [outcome] at baseline.
3Model 2: model 1 plus Duric acid as a continuous covariate.
4Model 3: model 1 plus DapoCIII as a continuous covariate.
5Model 4: model 1 plus Duric acid and DapoCIII as continuous covariates.
6DFST and D24-h mean uric acid yielded nearly identical results in models 2 and 4. Only FST uric acid results are
presented.
7% Variance: proportion of variance explained by variable or model = (type III sum of squares/corrected total sum of
squares) 3 100.
8Results shown for DFST apoCIII.
9Results shown for DPP apoCIII.
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experimental groups. Another limitation is that that the partici-
pants consumed ad libitum diets with the study beverages during
the 12-d outpatient period, which precludes our drawing con-
clusions concerning the effects of precise amounts of sugar
consumption. Also, in interventions studies lasting 3–10 wk,
subjects consumed significantly more energy and gained more
weight when consuming sugar-sweetened beverage/snacks
compared with artificially sweetened beverages/snacks (41–43).
Therefore, variations in outpatient energy intake likely explain
the nominally significant dose-response effect of HFCS con-
sumption on body weight gain. This dose-dependent body
weight gain could have mediated the dose-dependent increases
in the other outcomes. However, the highly significant effects of
HFCS-dose in the statistical models adjusted for body weight
gain suggest that the dose-dependent effects of HFCS on risk
factors were largely independent of body weight gain. This
suggestion is supported by reports of increases of risk factors in
subjects who consumed high-sugar diets as part of energy-balanced
diet protocols and, therefore, did not gain weight (44–47).
The added sugar component of the typical US diet consists of
at least as much sucrose as HFCS (48); therefore, a limitation of
this study is that we did not also investigate the dose-response
effects of sucrose consumption. However, older and recent
studies suggest that consumption of sucrose beverages also in-
creases risk factors for CVD (19, 47, 49, 50). The duration of the
2-wk intervention could be considered a potential limitation. It
also, however, indicates how quickly excess sugar consumption
can initiate metabolic dysregulation. Certainly, the results from
sucrose intervention studies ranging from 6 wk to 6 mo (19, 44,
47, 51) and the numerous epidemiologic studies demonstrating
associations between CVD risk factors and sugar consumption
(1, 2) provide evidence that the highly significant results reported
here would unlikely be transient during a longer intervention
period.
In conclusion, this study demonstrates that consumption of
beverages providing 10%, 17.5%, or 25% Ereq from HFCS re-
sults in dose-dependent increases of established risk factors for
CVD within 2 wk in young men and women. Concentrations of
non–HDL cholesterol, LDL cholesterol, apoB, uric acid, post-
prandial apoCIII, and postprandial triglyceride increased as the
dose of HFCS consumed increased, and they were significant
compared with consumption of 0% Ereq-HFCS beverages for
most outcomes (12 of 16) in the 25% Ereq-HFCS group, for half
(8 of 16) of the outcomes in the 17% Ereq-HFCS group, and for
postprandial triglyceride in the 10% Ereq-HFCS group. These
results provide a plausible mechanistic link to the results of the
recent report that there is increased risk of CVD mortality with
increased intake of added sugar across quintiles (2). Both studies
suggest that humans are sensitive to the adverse effects of
sustained sugar consumption at a relatively wide range of in-
take and highlight the need for carefully controlled diet in-
tervention studies to determine prudent amounts of added sugar
consumption.
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